Show simple item record

dc.contributor.authorKrome, Anna K
dc.contributor.authorBecker, Tim
dc.contributor.authorKehraus, Stefan
dc.contributor.authorSchiefer, Andrea
dc.contributor.authorSteinebach, Christian
dc.contributor.authorAden, Tilman
dc.contributor.authorFrohberger, Stefan J
dc.contributor.authorLópez Mármol, Álvaro
dc.contributor.authorKapote, Dnyaneshwar
dc.contributor.authorJansen, Rolf
dc.contributor.authorChaverra-Muñoz, Lillibeth
dc.contributor.authorHübner, Marc P
dc.contributor.authorPfarr, Kenneth
dc.contributor.authorHesterkamp, Thomas
dc.contributor.authorStadler, Marc
dc.contributor.authorGütschow, Michael
dc.contributor.authorKönig, Gabriele M
dc.contributor.authorHoerauf, Achim
dc.contributor.authorWagner, Karl G
dc.date.accessioned2020-12-11T14:24:13Z
dc.date.available2020-12-11T14:24:13Z
dc.date.issued2020-11-18
dc.identifier.citationPharmaceutics. 2020 Nov 18;12(11):1105. doi: 10.3390/pharmaceutics12111105.en_US
dc.identifier.issn1999-4923
dc.identifier.pmid33217948
dc.identifier.doi10.3390/pharmaceutics12111105
dc.identifier.urihttp://hdl.handle.net/10033/622647
dc.description.abstractNovel-antibiotics are urgently needed to combat an increase in morbidity and mortality due to resistant bacteria. The preclinical candidate corallopyronin A (CorA) is a potent antibiotic against Gram-positive and some Gram-negative pathogens for which a solid oral formulation was needed for further preclinical testing of the active pharmaceutical ingredient (API). The neat API CorA is poorly water-soluble and instable at room temperature, both crucial characteristics to be addressed and overcome for use as an oral antibiotic. Therefore, amorphous solid dispersion (ASD) was chosen as formulation principle. The formulations were prepared by spray-drying, comprising the water-soluble polymers povidone and copovidone. Stability (high-performance liquid chromatography, Fourier-transform-infrared spectroscopy, differential scanning calorimetry), dissolution (biphasic dissolution), and solubility (biphasic dissolution, Pion's T3 apparatus) properties were analyzed. Pharmacokinetic evaluations after intravenous and oral administration were conducted in BALB/c mice. The results demonstrated that the ASD formulation principle is a suitable stability- and solubility-enhancing oral formulation strategy for the API CorA to be used in preclinical and clinical trials and as a potential market product.en_US
dc.language.isoenen_US
dc.publisherMDPIen_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectanthelminticen_US
dc.subjectantibioticen_US
dc.subjectbiphasic dissolution (BiPHa+)en_US
dc.subjectcopovidone (PVP/VA)en_US
dc.subjectcorallopyronin A (CorA)en_US
dc.subjectpharmacokinetic analysisen_US
dc.subjectpovidone (PVP)en_US
dc.subjectsolubility enhanced formulationen_US
dc.subjectspray-dried amorphous solid dispersion (ASD)en_US
dc.subjectstability enhanced formulationen_US
dc.titleSolubility and Stability Enhanced Oral Formulations for the Anti-Infective Corallopyronin A.en_US
dc.typeArticleen_US
dc.contributor.departmentHZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.en_US
dc.identifier.journalPharmaceuticsen_US
dc.source.volume12
dc.source.issue11
refterms.dateFOA2020-12-11T14:24:14Z
dc.source.journaltitlePharmaceutics
dc.source.countrySwitzerland


Files in this item

Thumbnail
Name:
Krome et al.pdf
Size:
2.932Mb
Format:
PDF
Description:
Open Access publication

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's license is described as Attribution 4.0 International